Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.93 Million EUR | -90.98% |
| 2022 | 17.22 Million USD | -20.52% |
| 2021 | 21.67 Million USD | 326.6% |
| 2020 | -9.56 Million USD | 65.9% |
| 2019 | -28.04 Million USD | -32.98% |
| 2018 | -21.08 Million EUR | 42.95% |
| 2017 | -36.96 Million EUR | -291.13% |
| 2016 | 19.34 Million EUR | -92.21% |
| 2015 | 248.19 Million EUR | 238.5% |
| 2014 | 73.32 Million EUR | 6.68% |
| 2013 | 68.73 Million EUR | 254.93% |
| 2012 | 19.36 Million EUR | 154.84% |
| 2011 | 7.59 Million EUR | 110.67% |
| 2010 | 3.6 Million EUR | -10.94% |
| 2009 | 4.05 Million EUR | -56.92% |
| 2008 | 9.4 Million EUR | 8004.31% |
| 2007 | 116 Thousand EUR | 133.72% |
| 2006 | -344 Thousand EUR | -141.05% |
| 2005 | 838 Thousand EUR | 138.14% |
| 2004 | -2.19 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 40.7 Million USD | 0.0% |
| 2024 Q1 | 41 Million USD | 1284.03% |
| 2023 Q2 | 1.63 Million USD | 102.92% |
| 2023 FY | 1.55 Million USD | -90.98% |
| 2023 Q4 | -7.29 Million USD | -115.18% |
| 2023 Q3 | -3.39 Million USD | -307.44% |
| 2023 Q1 | 805.94 Thousand USD | -91.86% |
| 2022 FY | 17.22 Million USD | -20.52% |
| 2022 Q4 | 9.89 Million USD | 115.9% |
| 2022 Q3 | 4.58 Million USD | -46.04% |
| 2022 Q2 | 8.49 Million USD | 0.0% |
| 2021 FY | 21.67 Million USD | 326.6% |
| 2021 Q4 | 32.08 Million USD | 0.0% |
| 2021 Q2 | -6.79 Million USD | 0.0% |
| 2020 Q2 | -3.38 Million USD | 0.0% |
| 2020 FY | -9.56 Million USD | 65.9% |
| 2020 Q4 | -5.94 Million USD | 0.0% |
| 2019 Q4 | -4.2 Million USD | 0.0% |
| 2019 FY | -28.04 Million USD | -32.98% |
| 2019 Q2 | -23.98 Million USD | 0.0% |
| 2018 FY | -21.08 Million EUR | 42.95% |
| 2017 FY | -36.96 Million EUR | -291.13% |
| 2016 FY | 19.34 Million EUR | -92.21% |
| 2015 FY | 248.19 Million EUR | 238.5% |
| 2014 FY | 73.32 Million EUR | 6.68% |
| 2013 FY | 68.73 Million EUR | 254.93% |
| 2012 FY | 19.36 Million EUR | 154.84% |
| 2011 FY | 7.59 Million EUR | 110.67% |
| 2010 FY | 3.6 Million EUR | -10.94% |
| 2009 FY | 4.05 Million EUR | -56.92% |
| 2008 FY | 9.4 Million EUR | 8004.31% |
| 2007 FY | 116 Thousand EUR | 133.72% |
| 2006 FY | -344 Thousand EUR | -141.05% |
| 2005 FY | 838 Thousand EUR | 138.14% |
| 2004 FY | -2.19 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 100.083% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 100.061% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 100.594% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 91.273% |
| Novartis AG | 14.85 Billion USD | 100.033% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | 102.744% |